Agenus Inc. (NASDAQ:AGEN) – Investment analysts at William Blair raised their Q1 2018 earnings per share (EPS) estimates for Agenus in a research note issued to investors on Monday. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings of ($0.34) per share for the quarter, up from their previous forecast of ($0.36). William Blair also issued estimates for Agenus’ Q2 2018 earnings at ($0.33) EPS, Q3 2018 earnings at ($0.31) EPS, Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($1.32) EPS, FY2019 earnings at ($1.32) EPS, FY2020 earnings at ($1.23) EPS and FY2021 earnings at ($1.03) EPS.
Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. The firm had revenue of $4.21 million during the quarter, compared to the consensus estimate of $6.66 million. During the same period last year, the firm posted ($0.33) earnings per share. The company’s revenue for the quarter was down 36.1% compared to the same quarter last year.
TRADEMARK VIOLATION WARNING: “Agenus Inc. Forecasted to Earn Q1 2018 Earnings of ($0.34) Per Share (AGEN)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/10/27/agenus-inc-forecasted-to-earn-q1-2018-earnings-of-0-34-per-share-agen.html.
AGEN has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Wednesday. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 price objective on shares of Agenus in a report on Friday, August 4th. ValuEngine upgraded shares of Agenus from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th. Finally, BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a report on Monday, July 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $5.81.
Agenus (AGEN) traded up 2.53% on Wednesday, reaching $3.65. The company had a trading volume of 2,505,985 shares. The company’s 50-day moving average price is $4.34 and its 200 day moving average price is $3.96. The firm’s market capitalization is $363.95 million. Agenus has a 1-year low of $3.20 and a 1-year high of $5.91.
Several large investors have recently bought and sold shares of AGEN. Bank of New York Mellon Corp boosted its position in Agenus by 38.1% in the 1st quarter. Bank of New York Mellon Corp now owns 560,799 shares of the biotechnology company’s stock valued at $2,114,000 after buying an additional 154,715 shares during the period. UBS Asset Management Americas Inc. boosted its position in Agenus by 203.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 34,833 shares during the period. SG Americas Securities LLC boosted its position in Agenus by 175.7% in the 1st quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares during the period. American International Group Inc. boosted its position in Agenus by 7.1% in the 1st quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,984 shares during the period. Finally, Neuberger Berman Group LLC purchased a new position in Agenus in the 1st quarter valued at approximately $273,000. 39.57% of the stock is owned by hedge funds and other institutional investors.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.